Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PATANASE Nasal Spray in Perennial Allergic Rhinitis
NCT00789555Phase 4Completed
- Sponsor
- Alcon Inc.
- Start
- Nov 2008
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of olopatadine in perennial allergic rhinitis (PAR) (3 arms), sponsored by Alcon Inc. Primary endpoints: Percentage of Subjects With Clinically Relevant Change From Baseline in Nasal Examination Parameters at 12 months and Self-Rated Relief Assessment at 30 days. Started Nov 2008; status: completed.
02
Drugs
olopatadine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00789555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00789555.